Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I):



(I)

wherein:

R^1 represents phenyl ~~which may be~~ optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of: halogen; trifluoromethyl; -C_{1-6}alkyl optionally substituted by $COOR^{15}$; -C_{1-6}alkoxy optionally substituted by $COOR^{15}$; hydroxy; oxo; cyano; -C_{1-6}alkyl-cyano; C_{2-6} alkenyl ~~C_{1-6}alkenyl~~ optionally substituted by $COOR^{15}$; C_{3-7}cycloalkyl; C_{1-6}alkylsulfonyl; C_{2-6}alkenoxy ~~C_{1-6}alkenoxy~~; C_{1-6}alkylthio; $NR^{15}R^{16}$; -C_{1-6}alkyl-aryl; aryl; -CO-aryl optionally substituted by halogen; -CO-heteroaryl; -CO-heterocyclyl; -$COOR^{15}$; -COR^{15}; -$CONR^{15}R^{16}$ ~~optionally substituted by C_{1-6}alkyl, halogen or C_{1-6}alkylC_{1-6}alkoxy~~; and -C_{1-6}alkyl-CO-aryl groups; and in which

R^{15} and R^{16} independently represent hydrogen, C_{1-6}alkyl or C_{3-8}cycloalkyl or together may be fused to form a 5- to 7-membered non-aromatic heterocyclic ring optionally interrupted by an O or S atom and optionally substituted by a halogen, C_{1-6}alkyl or C_{1-6}alkylC_{1-6}alkoxy group;

Z represents CO;

r is 0;

p is 1;

m is 0;

R^3 represents a group of formula (i):



(i)

wherein

f is 0;

g is 2;

h is 1;

k is 0; and

R^{13} represents C_{1-6}alkyl or C_{3-8}cycloalkyl;

or a pharmaceutically acceptable salt thereof.

2-11. (Cancelled)

Add the following new claims:

12. (Currently amended) A compound according to claim 1 wherein R^1 is phenyl ~~which may be~~ optionally substituted by 1, 2 or 3 substituents which may be the same or different and which are selected from the group consisting of: chlorine, fluorine, bromine; trifluoromethyl; methyl, ethyl, isopropyl, propyl, t-butyl (optionally substituted by COOH, COOMe or COOEt); methoxy, butoxy, -OCH(Me)$_2$, –OC(Me)$_3$ (optionally substituted by COOH or COOMe); hydroxy; oxo; cyano; –CH$_2$-CN; ethenyl (optionally substituted by COOMe); cyclopentyl; –SO$_2$Me; –OCH$_2$CH=CH$_2$; –S-ethyl; N(Me)$_2$; benzyl; phenyl; –CO-phenyl (optionally substituted by chlorine); –CO-azetidinyl; –CO-tetrahydropyranyl; COOH, COOMe, COOt-butyl; –CO-methyl, -CO-ethyl, -CO-isopropyl, -CO-cyclopropyl, -CO-cyclobutyl, -CO-cyclopentyl, -CO-cyclohexyl; –CONH$_2$, -CO-pyrrolidinyl, -CO-morpholinyl, -CO-piperazinyl, -CO-piperidinyl, -CO-thiomorpholinyl (optionally substituted by methyl, fluorine and –CH$_2$OMe); or –CH$_2$COphenyl groups;

or a pharmaceutically acceptable salt thereof.

13. (Previously presented) A compound according to claim 1 wherein R^1 is phenyl substituted by C_{1-6}alkylsulfonyl.

14. (Previously presented) A compound according to claim 1 wherein R^1 is phenyl substituted by SO_2Me.

15. (Previously presented) A compound according to claim 1 wherein R^1 is phenyl substituted by SO_2Me at the para position.

16. (Previously presented) A compound according to claim 1 wherein -O-R^3 is present at the para position of the phenyl group with respect to the rest of the compound.

17. (Previously presented) A compound according to claim 1 wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

18. (Previously presented) A compound according to claim 13, wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

19. (Previously presented) A compound according to claim 14, wherein R^{13} represents isopropyl, cyclopropyl or cyclobutyl.

20. (Previously presented) A compound which is 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine or a pharmaceutically acceptable salt thereof.

21. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

22. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human ~~host~~ in need thereof an effective amount of a compound of formula (I) as defined in claims 1 or a pharmaceutically acceptable salt thereof.

23. (Previously presented) A method of treatment according to claim 21 in which the disease is allergic rhinitis.

24. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 18 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

25. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human ~~host~~ in need thereof an effective amount of a compound of formula (I) as defined in claims 18 or a pharmaceutically acceptable salt thereof.

26. (Previously presented) A method of treatment according to claim 25 in which the disease is allergic rhinitis.

27. (Previously presented) A pharmaceutical composition which comprises a compound of formula (I) as defined in claim 19 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

28. (Currently amended) A method of treatment of diseases of the upper respiratory tract which comprises administering to a human ~~host~~ in need thereof an effective amount of a compound of formula (I) as defined in claims 19 or a pharmaceutically acceptable salt thereof.

29. (Previously presented) A method of treatment according to claim 28 in which the disease is allergic rhinitis.